SCNLF (Scancell Holdings) Total Equity: $-11.18 Mil (As of Oct. 2025)


SCNLF Scancell Holdings PLC SCNLF
20 GF Score
Price $0.28
! 2 Warning Signs
View Full Analysis

What is Scancell Holdings Total Equity?

Scancell Holdings SCNLF 20 Total Equity is $-11.18 Mil as of Oct. 2025. GuruFocus rates SCNLF with a GF Score™ of 20/100. The stock has 2 warning signs investors should review.

Scancell Holdings's total equity for the quarter that ended in Oct. 2025 was $-11.18 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Scancell Holdings Total Equity Historical Data

* Premium members only.

The historical data trend for Scancell Holdings's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Scancell Holdings Total Equity Chart

Scancell Holdings Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.03 1.80 -12.02 -4.39 -5.04

Scancell Holdings Semi-Annual Data
Apr16 Oct16 Apr17 Oct17 Apr18 Oct18 Apr19 Oct19 Apr20 Oct20 Apr21 Oct21 Apr22 Oct22 Apr23 Oct23 Apr24 Oct24 Apr25 Oct25
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10.19 -4.39 -20.21 -5.04 -11.18
SCNLF
20GF Score
Scancell Holdings PLC SCNLF
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Scancell Holdings Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Scancell Holdings's Total Equity for the fiscal year that ended in Apr. 2025 is calculated as

Total Equity=Total Assets(Q: Apr. 2025 )-Total Liabilities(Q: Apr. 2025 )
=30.342-35.381
=-5.04

Scancell Holdings's Total Equity for the quarter that ended in Oct. 2025 is calculated as

Total Equity=Total Assets(Q: Oct. 2025 )-Total Liabilities(Q: Oct. 2025 )
=20.53-31.708
=-11.18

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $-11.18 Mil mean?
Scancell Holdings (SCNLF) has a Total Equity of $-11.18 Mil as of Oct. 2025. The total amount of equity as record on a company's balance sheet. View historical data for Scancell Holdings and its competitors.
Is Scancell Holdings' Total Equity too high?
Scancell Holdings' current Total Equity is $-11.18 Mil. Overall, Scancell Holdings has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Scancell Holdings' Total Equity compare to VRTX and REGN?
Scancell Holdings' Total Equity of $-11.18 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Scancell Holdings and its competitors. Scancell Holdings's current Total Equity is $-11.18 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Scancell Holdings stock overvalued right now?
Scancell Holdings (SCNLF) has a current Total Equity of $-11.18 Mil. The current Total Equity is $-11.18 Mil. Scancell Holdings' overall GF Score™ is 20/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Scancell Holdings (SCNLF), the current Total Equity is $-11.18 Mil as of Oct. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Scancell Holdings Business Description

Other Exchanges SCLP:UKSCP:Germany
Address Sanders Road, Unit 202, Bellhouse Building, Oxford Science Park, Oxford, GBR, OX4 4GD
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
20GF Score

Get the complete analysis for SCNLF

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.28
Price